CCL27 and cancer: Studies were included if they focused on helper ILC subsets (ILC1s, ILC2s, ILC3s, or LTi cells), presented original data or comprehensive mechanistic reviews, addressed roles in autoimmune diseases and/or cancer, and provided insight into therapeutic applications or platforms, including CAR/CSR engineering, immune modulation, or CB/PSC-derived ILCs.